+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hepatitis B Therapeutics Market 2018-2022 - Product Image

Global Hepatitis B Therapeutics Market 2018-2022

  • ID: 4720698
  • Report
  • Region: Global
  • 110 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • MORE
About this market

Global hepatitis B therapeutics market is fragmented market, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development. These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.

Market Overview

Increasing prevalence of hepatitis B in infants

The increase in the prevalence of hepatitis B in infants, the companies are developing various and drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.

Low accessibility due to high cost of hepatitis B treatment

One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.

For the detailed list of factors that will drive and challenge the growth of the hepatitis B therapeutics market during the 2018-2022, view the report.

Competitive Landscape

The global hepatitis B therapeutics market is fairly fragmented and the market being in growth phase, the competition among companies is intense. Several companies are forming collaborations to increase their research toward the hepatitis B drug development. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION
  • Segmentation by application
  • Comparison by application
  • Drugs - Market size and forecast 2017-2022
  • Vaccines - Market size and forecast 2017-2022
  • Market opportunity by application
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Strategic alliances
  • Strong pipeline
  • New technological advancements
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global infectious disease treatment market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global hepatitis B therapeutics market - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global hepatitis B therapeutics market - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 20
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Global hepatitis B therapeutics pipeline: Overview
Exhibit 20: Application - Market share 2017-2022 (%)
Exhibit 21: Comparison by application
Exhibit 22: Drugs - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Drugs - Year-over-year growth 2018-2022 (%)
Exhibit 24: Vaccines - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Vaccines - Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Global - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb - Overview
Exhibit 46: Bristol-Myers Squibb - Business segments
Exhibit 47: Bristol-Myers Squibb - Organizational developments
Exhibit 48: Bristol-Myers Squibb - Geographic focus
Exhibit 49: Bristol-Myers Squibb - Key offerings
Exhibit 50: Bristol-Myers Squibb - Key customers
Exhibit 51: F. Hoffmann-La Roche - Overview
Exhibit 52: F. Hoffmann-La Roche - Business segments
Exhibit 53: F. Hoffmann-La Roche - Organizational developments
Exhibit 54: F. Hoffmann-La Roche - Geographic focus
Exhibit 55: F. Hoffmann-La Roche - Segment focus
Exhibit 56: F. Hoffmann-La Roche - Key offerings
Exhibit 57: F. Hoffmann-La Roche - Key customers
Exhibit 58: Gilead - Overview
Exhibit 59: Gilead - Business segments
Exhibit 60: Gilead - Organizational developments
Exhibit 61: Gilead - Geographic focus
Exhibit 62: Gilead - Key offerings
Exhibit 63: Gilead - Key customers
Exhibit 64: GlaxoSmithKline - Overview
Exhibit 65: GlaxoSmithKline - Business segments
Exhibit 66: GlaxoSmithKline - Organizational developments
Exhibit 67: GlaxoSmithKline - Geographic focus
Exhibit 68: GlaxoSmithKline - Segment focus
Exhibit 69: GlaxoSmithKline - Key offerings
Exhibit 70: GlaxoSmithKline - Key customers
Exhibit 71: Merck Sharp & Dohme - Overview
Exhibit 72: Merck Sharp & Dohme - Business segments
Exhibit 73: Merck Sharp & Dohme - Organizational developments
Exhibit 74: Merck Sharp & Dohme - Geographic focus
Exhibit 75: Merck Sharp & Dohme - Segment focus
Exhibit 76: Merck Sharp & Dohme - Key offerings
Exhibit 77: Merck Sharp & Dohme - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • MORE
Global Hepatitis B Therapeutics Market 2018-2022

The author of the report recognizes the following companies as the key players in the global hepatitis B therapeutics market: Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, GlaxoSmithKline, Merck Sharp & Dohme.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strategic collaboration between pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market.”

According to the report, one of the major drivers for this market is the increase in the prevalence of hepatitis B in infants, the companies are developing various vaccines and drugs against hepatitis B virus. This leads to an increase in the global hepatitis B therapeutics market growth during the forecast period.

Further, the report states that one of the major factors hindering the growth of this market is the low accessibility due to the high cost of hepatitis B treatment is one of the biggest challenges for the goal aiming to eliminate hepatitis B by 2030.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme
Note: Product cover images may vary from those shown
Adroll
adroll